Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Parsaclisib plus ruxolitinib in myelofibrosis with suboptimal ruxolitinib response
CTR20212200Phase 3Terminated
- Sponsor
- Incyte
- Start
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of parsaclisib in primary myelofibrosis (PMF), myelofibrosis (MF), sponsored by Incyte. Started Sep 2021; status: terminated.
02
Drugs
parsaclisib
03
Conditions
primary myelofibrosis (PMF)myelofibrosis (MF)
Beyond the preview
Go deeper on CTR20212200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212200.